ACADIA Pharmaceuticals (ACAD) investor relations material

Executive summary

• Q1 2026 revenue reached $268.1 million, up 11% year-over-year, driven by strong growth in DAYBUE and NUPLAZID sales.

• DAYBUE net sales were $101.2 million, up 20% year-over-year, with the highest growth since Q3 2024 and strong uptake of DAYBUE STIX.

• NUPLAZID net sales were $167 million, up 6% year-over-year on an adjusted basis, with normalized refill dynamics and strong referral growth.

• Net income for Q1 2026 was $3.6 million, down from $19 million in Q1 2025, primarily due to higher SG&A expenses.

• Cash and investments totaled $851.5 million at quarter end, providing strong liquidity.

Financial highlights

• Total Q1 2026 revenue: $268.1 million, up 11% year-over-year.

• DAYBUE net sales: $101.2 million (up 20% YoY); NUPLAZID net sales: $166.9 million (up 6% YoY, non-GAAP adjusted).

• R&D expenses: $76.9 million, nearly flat year-over-year.

• SG&A expenses: $171 million, up from $126.4 million in Q1 2025, reflecting increased commercial investment.

• Diluted EPS: $0.02, compared to $0.11 in Q1 2025.

Outlook and guidance

• Reaffirmed full-year 2026 total revenue guidance: $1.22–$1.28 billion.

• NUPLAZID net sales expected at $760–$790 million; DAYBUE net sales at $460–$490 million.

• R&D expense guidance: $385–$410 million; SG&A expense guidance: $660–$700 million.

• Anticipated topline results for remlifanserin (Alzheimer’s Disease Psychosis) in August–October 2026 and trofinetide (Japan Phase 3) in September–November 2026.

• Revenue expected to be back-end loaded, with greater sales in H2 2026 due to expanded field force and broader DAYBUE STIX adoption.